Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumoursHajime Yurugi, Krishnaraj Rajalingam, Laurent Désaubry et al.|Oncogene|2017Cited by 48
ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesisKatarzyna Bogucka, Krishnaraj Rajalingam, Fédérico Marini et al.|Cancer Gene Therapy|2020Cited by 15
Correction: ERK3/MAPK6 is required for KRAS-mediated NSCLC tumorigenesisKatarzyna Bogucka, Krishnaraj Rajalingam, Margarita Schlackow et al.|Cancer Gene Therapy|2020Cited by 0